First and foremost, rTIMP2 treatment reduced tumor burden in both wt and mT2 mice, consistent with previous reports that TIMP2 demonstrates significant anti-tumor activity (18–20, 46, 48). This evidence concerns the gene TIMP2 and neoplasm.